Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - gliclazide, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; povidone; sodium starch glycollate type a; purified talc; magnesium stearate

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - gliclazide -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - gliclazide -

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - gliclazide - tablets - 80 milligram

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

les laboratoires servier - gliclazide - modified-release tablets - 30 milligram

Καναδάς - Αγγλικά - Health Canada

avanstra inc - gliclazide - tablet - 80mg - gliclazide 80mg - sulfonylureas

Καναδάς - Αγγλικά - Health Canada

sandoz canada incorporated - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas

Καναδάς - Αγγλικά - Health Canada

sandoz canada incorporated - gliclazide - tablet (extended-release) - 60mg - gliclazide 60mg - sulfonylureas

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: sodium acetate; magnesium stearate; lactose monohydrate; silicon dioxide; mannitol; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; mannitol; silicon dioxide; hypromellose; magnesium stearate; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.